Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Libo Sun

Showing results (141-150 of 148) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 148 results.
Blood Cancer Journal|April 7, 2026
Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromesAmer M Zeidan, Valeria Santini, María Díez-Campelo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2021
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory MyelofibrosisJohn Mascarenhas, Rami S Komrokji, Francesca Palandri, et al.
Leukemia|January 12, 2026
Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstatValeria Santini, Amer M Zeidan, Koen Van Eygen, et al.
Blood Cancer Journal|December 31, 2025
Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDSRami S Komrokji, Valeria Santini, Amer M Zeidan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2020
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II StudyDavid P Steensma, Pierre Fenaux, Koen Van Eygen, et al.
Nature Communications|January 4, 2024
Spin-related Cu-Co pair to increase electrochemical ammonia generation on high-entropy oxidesShengnan Sun, Chencheng Dai, Peng Zhao, et al.
British Journal of Haematology|November 30, 2025
Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trialRami S Komrokji, Valeria Santini, Uwe Platzbecker, et al.
Lancet (London, England)|December 4, 2023
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trialUwe Platzbecker, Valeria Santini, Pierre Fenaux, et al.
Pageof 15

Showing results (141-150 of 148) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 148 results.
Blood Cancer Journal|April 7, 2026
Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromesAmer M Zeidan, Valeria Santini, María Díez-Campelo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2021
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory MyelofibrosisJohn Mascarenhas, Rami S Komrokji, Francesca Palandri, et al.
Leukemia|January 12, 2026
Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstatValeria Santini, Amer M Zeidan, Koen Van Eygen, et al.
Blood Cancer Journal|December 31, 2025
Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDSRami S Komrokji, Valeria Santini, Amer M Zeidan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2020
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II StudyDavid P Steensma, Pierre Fenaux, Koen Van Eygen, et al.
Nature Communications|January 4, 2024
Spin-related Cu-Co pair to increase electrochemical ammonia generation on high-entropy oxidesShengnan Sun, Chencheng Dai, Peng Zhao, et al.
British Journal of Haematology|November 30, 2025
Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trialRami S Komrokji, Valeria Santini, Uwe Platzbecker, et al.
Lancet (London, England)|December 4, 2023
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trialUwe Platzbecker, Valeria Santini, Pierre Fenaux, et al.
Pageof 15